Selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AI), used as a complementary treatment of breast cancers with positive estrogen receptors, reduce the endogenous production of estrogens after menopause. This evidence concerns the gene ESR1 and breast carcinoma.